Drug Database
DI

Divaza (Divaza)

✓ Approved

Materia Medica Holding · 小分子 · 小分子

什么是 Divaza?

Divaza 是一种小分子,由Materia Medica Holding研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Divaza
公司Materia Medica Holding
药物类别小分子
给药途径Oral (PO)
状态Approved

治疗适应症

Divaza 针对 4 个适应症,涉及 3 个治疗领域。

治疗领域疾病/病症分期
Psychiatric disordersAnxiety✓ Approved
Psychiatric disordersBipolar I disorder✓ Approved
Nervous system disordersHeadache✓ Approved
Ear and labyrinth disordersVertigo✓ Approved

相关研究文献

PubMedCerebrovascular diseases (Basel, Switzerland)2021-05-28

Efficacy and Safety of Divaza for the Correction of Oxidative Disturbances in Patients with Cerebral Atherosclerosis: A Randomized Controlled Trial.

Lashch Nataliia U NU, Kamchatnov Pavel R PR, Fedorova Tatiana N TN, Muzychuk Olga A OA et al.

The objective of this study was to determine if Divaza, a drug with nootropic and antioxidant effects, was safe and effective for the correction of oxidative disturbances and to stabilize cognitive impairment in patients with cerebral atherosclerosis. The study design consisted of a 12-week multicenter, randomized, double-blind, placebo-controlled, prospective trial in parallel groups. The setting in which the study was conducted comprised 10 clinical centers across the Russian Federation. Patients were randomized into 2 groups and instructed to take either 2 tablets of the study drug or a placebo 3 times per day in conjunction with basic therapy. The primary outcome was a change in the average endogenous antioxidant potential after the completion of the study. The blood indicators of the oxidative stress (OS) were analyzed at the baseline and then after 12 weeks of therapy using iron-induced chemiluminescence analysis. The Montreal cognitive assessment test was used as a secondary outcome measure to evaluate cognitive impairment at the end of the study. 124 outpatients with a mean age of 60.7 ± 7.6 years were enrolled and randomly assigned to receive Divaza (n = 65) or a placebo (n = 59). An improvement of cognitive function was observed in all patients of the Divaza group at the end of the treatment; this was significantly better than the placebo group (100 [100] vs. 89.5 [89.1]%, respectively, p = 0.0272 [p = 0.0128]). The administration of Divaza restored the activity of the endogenous antioxidant system. The change in the average level of lipoprotein resistance to oxidation after 12 weeks of therapy, compared to the baseline, was significantly higher in the Divaza group (14.8 ± 14.7 [14.8 ± 14.7] seconds latent period vs. 6.4 ± 16.9 [6.9 ± 16.7] seconds in the placebo group (p = 0.007 [p = 0.0107]). Divaza is a safe and effective therapeutic option for attenuating OS and recovery of cognitive impairment in patients with cerebral atherosclerosis.

PMID 34044407
阅读全文 →
PubMedEuropean neurology2020-11-18

Treatment of Cognitive Impairment and the Role of Demographic Factors in Disease Progression: The Final Results of the Russian Observational Program "DIAMANT".

Parfenov Vladimir Anatolyevich VA, Zhivolupov Sergey Anatolyevich SA, Poverennova Irina Evgenyevna IE, Nesterova Marina Valentinovna MV et al.

Chronic cerebral ischemia (CCI) is a form of cerebrovascular disease manifested as a vascular cognitive impairment (VCI). The management of the patients with CCI is determined by a healthy lifestyle and early therapy aimed at correcting and preventing this disease. Divaza is a drug with endothelial protective and nootropic effects. We present the final efficacy and safety analysis of all-Russian, open-label, prospective, observational, multicenter study of Divaza and emphasize the role of demographic and socioeconomic factors in cognitive disorder (CD) progression. CCI patients (n = 2,583) with or without CD were enrolled. Patients received Divaza (2 tablets 3 times per day for 12 weeks). Montreal Cognitive Assessment (MoCA) testing was required. The change in the mean MoCA score post-treatment was used as the primary endpoint. As the secondary endpoints, the number of patients with a MoCA <26 and ≤17 (dementia); the percentage of patients with a MoCA score improvement in different age groups; the dynamics of mean MoCA score in age groups; and the relationship between CD and sex or regional social/economic factors were assessed. Divaza therapy led to a significant improvement: the mean MoCA score was up to 20% higher post-treatment (Wilcoxon test, p < 0.0001 vs. baseline). The number of participants with MoCA ≥26 increased by 33.6%. The number of patients with dementia was 4.1 times less after therapy (p < 0.00001 vs. baseline). Divaza improved cognitive functions of patients in each age group. Findings demonstrate that regional socioeconomic factors contribute to CD development and severity. The observed divergence between sexes was a result of a larger number of women enrolled. The study confirmed the safety of Divaza. In the study, we observed the efficacy of Divaza for the treatment of CD: a therapy contributed to an increase in the mean MoCA score and the positive dynamics in the number of patients with cognitive improvement.

PMID 33202402
阅读全文 →
PubMedZhurnal nevrologii i psikhiatrii imeni S.S. Korsakova2018-07-25

[Diagnosis and treatment of cognitive impairment in patients with chronic cerebral ischemia: the results of observational Russian program DIAMANT].

Parfenov V A VA, Zhivolupov S A SA, Nikulina K V KV, Poverennova I E IE et al.

To investigate the efficacy of divaza in outpatients with cognitive disorders and chronic brain ischemia (CBI). The non-interventional observational program included the data of 2583 outpatients with CBI from 30 cities (8 federal okrugs of the Russian Federation) who were on outpatient neurological treatment and received divaza in a dose of 2 tablets three times a day from Oct 2016 to Jan 2017. Cognitive functions were evaluated using the MoCA scale before and after 3 months of treatment. Cognitive disorders were identified in 90.7% of patients (<26 MoCA scores). After treatment, the mean MoCA score increased from 19.58±5.13 to 23.99±4.21 (p<0.0001), the number of patients with normal cognitive functions rate (≥26 scores) increased from 9.3 to 41.3%, the number of patients with marked cognitive impairment decreased. The drug was well-tolerated by old and very old patients, adverse events were observed rarely (0.6% of cases). The majority of doctors (88.4%) noticed the effect of divaza as significant improvement or improvement, and 89.6% of patients valued the effect to be excellent or good. The use of divaza, the drug with endothelioprotective and nootropic effects, is pathogenetically justified and promising in patients with cognitive disorders of vascular etiology.

PMID 30040796
阅读全文 →
PubMedZhurnal nevrologii i psikhiatrii imeni S.S. Korsakova2018-01-30

[Divasa in the treatment and prevention of cerebrovascular diseases].

Shavlovskaya O A OA

Disturbances of hemorheology, hemostasis and fibrinolysis play an important role in the pathogenesis and pathophysiology of chronic cerebral ischemia. Physiological functioning of the endothelium is disturbed under the action of damaging factors. Divaza is created on the basis of release-active antibodies to S100b protein and antibodies to endothelial NO-synthase. The efficacy of divaza in the treatment of chronic cerebral ischemia and related diseases (cognitive impairment, anxiety) was demonstrated. A normalizing effect of divaza in the dose of 2 tablets 3 times daily between meals during 12 weeks on endothelial function is shown.

PMID 29376993
阅读全文 →
PubMedZhurnal nevrologii i psikhiatrii imeni S.S. Korsakova2017-11-25

[Nitric oxide: from the mechanism of action to pharmacological effects in cerebrovascular diseases].

Fateeva V V VV, Vorobyova O V OV

The article presents the data of studies of nitric oxide (NO) in the pathogenesis of cerebrovascular diseases. It is emphasized that endothelial dysfunction contributes to the formation of cerebrovascular diseases. Generalized data on preparations with endothelioprotective effect, as well as own data on the use of the preparation 'Divaza' in patients of middle and advanced age with chronic cerebrovascular disease are given.

PMID 29171501
阅读全文 →
PubMedZhurnal nevrologii i psikhiatrii imeni S.S. Korsakova2017-10-21

[Results of multicenter study of efficacy and safety of divaza in the treatment of the asthenic and mild to moderate cognitive disorders in elderly and senile subjects].

Parfenov V А VА, Kamchatnov P R PR, Vorobyova О V ОV, Gustov А V АV et al.

To study the efficacy and safety of divasa in elderly and senile subjects with asthenic and mild to moderate cognitive disorders. The study included 126 patients with clinically significant asthenia and mild to moderate cognitive disorders. Asthenia was assessed with MFI-20, cognitive disorders with MMSE, clock drawing test and verbal association test. All patients were treated with divasa in dose 2 tablets 3 times a day. The efficacy and safety of divasa in asthenic and mild to moderate cognitive disorders in elderly and senile subjects were shown. There is a need for a multicenter placebo-controlled trial on the efficacy of divasa to treat cognitive and asthenic disorders in elderly patients.

PMID 29053120
阅读全文 →

注册免费账户还可查看另外 10 篇文献

免费注册查看全部文献 →

了解更多Divaza